1. Stocks
    2. /
  2. BioNTech Se (NASDAQ: BNTX)
    3. /

BioNTech Se (NASDAQ: BNTX) Share Price and News

$111.61 $-5.78 (-4.9%) Thursday, 19 December 2024 at 8:00:00 am Australian Eastern Daylight Time

BioNTech Se Chart and Price Data

About BioNTech Se

Last updated 19-12-2024, 08:00:00am AEDT
Current Price $111.61
Change $-5.78 (-4.9%)
Close Price $117.39
Open Price $116.00
Bid $109.00
Ask $118.00
Day Range $110.02 - $117.11
Year Range $76.53 - $131.49
Volume 776,240
Average Volume 904,840
Market Cap $28,143,078,600.00
Earnings Per Share $-2.15

    • BioNTech Se (NASDAQ: BNTX)
    Latest News

    A nurse administers a vaccine into the arm of a woman wearing a mask.
    International Stock News

    2 Nasdaq stocks bucking Monday's market drop

    | Dan Caplinger

    The Nasdaq Composite continued to lose ground, but these stocks held up.

    Read more »

    four excited doctors with their hands in the air
    ETFs

    Expert reveals top pandemic ETF play – up 58% in 12 months

    | Bernd Struben

    COVID variants are likely to drive longer-term demand for mRNA vaccines.

    Read more »

    A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
    Healthcare Shares

    Why the IDT (ASX:IDT) share price is rocketing 25% on Wednesday

    | Marc Sidarous

    The company claims it can make 100 million doses of mRNA vaccine within 18 months.

    Read more »

    man receiving covid 19 vaccine moderna biontech
    International Stock News

    Better biotech stock: Moderna vs. BioNTech

    | Jason Hawthorne

    The two companies behind the gene-based COVID vaccines are a lot different than you might think.

    Read more »

    health care worker giving a woman a COVID 19 vaccine
    International Stock News

    With COVID-19 variant threats rising, why are vaccine stocks falling?

    | Dan Caplinger

    Stock markets moved slightly higher despite general worries.

    Read more »

    woman receiving vaccine
    International Stock News

    3 reasons to buy BioNTech, and 1 reason to sell

    | Jason Hawthorne

    Despite the vaccine windfall and an impressive pipeline, shareholders might need the company's encore sooner than expected.

    Read more »

    Two laboratory researchers in white coats and gloves sit side by side with scientific equipment and a computer screen conducting medical related research.
    International Stock News

    Why BioNTech trounced the Market on Tuesday

    | Eric Volkman

    Shareholders might be getting a small present from the company before long.

    Read more »

    woman receiving covid 19 vaccine
    International Stock News

    If you thought these 2 big Nasdaq winners were done, think again

    | Dan Caplinger

    On a strong day for the Nasdaq, two highfliers stood out.

    Read more »

    teen showing that she has received her covid vaccination
    International Stock News

    Moderna files for FDA approval of its COVID vaccine in teens

    | Todd Campbell

    The company hopes to secure Emergency Use Authorization for its vaccine in children ages 12 to 18.

    Read more »

    A medical researcher in a white coat holds laboratory equipment and smiles.
    International Stock News

    Moderna's teen COVID-19 vaccine trial hits high marks

    | Cory Renauer

    The company should submit its request for the FDA to authorize the use of its vaccine in those 12 and…

    Read more »

    vaccine
    International Stock News

    BioNTech is no longer a buy, says analyst

    | Eric Volkman

    A Bryan Garnier prognosticator increases her price target despite the recommendation chop.

    Read more »

    health prffesional giving someone a vaccine
    International Stock News

    Pfizer and BioNTech's COVID-19 vaccine authorized by the FDA for adolescents

    | Brian Orelli, PhD

    Parents are pleased, but the move won't change much for the drug companies from a financial perspective.

    Read more »

    Profile

    since

    Note